Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27857330 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL2776839 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL29631961 | 0.91 | CTSK (0.52) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL11049954 | 0.90 | CASP3 (0.54) | CTSKCTSSCTSLCTSB | |
| SCHEMBL10974738 | 0.89 | ITGB3 (0.51) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL10974734 | 0.89 | CTSK (0.53) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL10929707 | 0.89 | CTSK (0.60) | CTSKCTSSCTSLCTSB | |
| SCHEMBL10933510 | 0.88 | ALDH1A1 (0.50) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL375882 | 0.86 | CTSS (0.56) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL10932889 | 0.85 | CTSK (0.49) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055913-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| CN-102365294-B | The dipeptide analogue of neurotrophic factor NGF and BDNF | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUKNAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII IMENI V.V.ZAKUSOVA RAMN (RU) | 2016-02-17 | — | — | CN | disclosed |
| EP-2587919-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | Azevan Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| CN-102365294-A | Dipeptide mimetics of ngf and bdnf neurotrophins | UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK | 2012-02-29 | — | — | CN | disclosed |
| WO-2012003436-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| EP-1578423-B1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| WO-1995013095-A2 | THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| US-5317021-A | Analgesics, anticonvulsants | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-05-31 | — | — | US | disclosed |
| US-5202340-A | Analgesics, anticonvulsants, anxiolytic agents, inhibitors for enkephalinases | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5017589-A | Analgesic, antianxiety, anticonvulsant | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0341081-A2 | Novel amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-11-08 | — | — | EP | disclosed |
| US-4552975-A | Manufacturing process for N-carbobenzyloxy-L-glutamic acid-α-cholinester salt | MORINGA MILK INDUSTRY, CO., LTD. (JP) | 1985-11-12 | — | — | US | disclosed |
| US-4426324-A | Immunopotentiating peptides | HOFFMANN-LA ROCHE INC. (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0026464-A2 | Peptides, their production, their use, and pharmaceutical preparations | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-08 | — | — | EP | disclosed |
| US-RE30473-E | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4105852-A | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CTSK 609/4885CTSS 505/4885CTSL 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.